Increasingly, antibodies are being used to treat and prevent viral infections. In the context of
HIV, efficacy is primarily attributed to dose-dependent neutralization potency and to a lesser …

The first clinical efficacy trials of a broadly neutralizing antibody (bNAb) resulted in less
benefit than expected and suggested that improvements are needed to prevent HIV …

Immunotherapy with passive administration of broadly neutralizing HIV-1 envelope-specific
antibodies (bnAbs) in the setting of established infection in vivo has yielded mixed results …

Broadly neutralizing antibodies (bNAbs) represent an alternative to drug therapy for the
treatment of HIV-1 infection. Immunotherapy with single bNAbs often leads to emergence of …

An increasing number of broadly neutralizing antibodies (bnAbs) are considered leads for
HIV-1 vaccine development and novel therapeutics. Here, we systematically explored the …

A considerable body of evidence suggests that Fc-dependent functions improve the capacity
of broadly neutralizing antibodies (BnAbs) to protect against and control HIV-1 infection. This …

Broadly neutralizing antibodies (BnAbs) protect macaques from cell-free simian/human
immunodeficiency virus (SHIV) challenge, but their efficacy against cell-associated SHIV is …

The development of an effective vaccine against HIV-1 has proven to be challenging.
Broadly neutralizing antibodies (bNAbs), whilst exhibiting neutralization breadth and …

The ability of several broadly neutralizing antibodies (bNAbs) to protect against HIV infection
is enhanced through Fc receptor binding. Antibody isotype modulates this effect, with IgG3 …

Delineating the key early events that lead to the development of broadly neutralizing anti-
HIV-1 antibodies during natural infection may help guide the development of immunogens …